UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Tustison N
(2023)
ANTsX neuroimaging-derived structural phenotypes of UK Biobank
Mutz J
(2022)
Anxiety disorders and age-related changes in physiology
in European Psychiatry
Mutz J
(2022)
Anxiety disorders and age-related changes in physiology.
in The British journal of psychiatry : the journal of mental science
Cecelja M
(2022)
Aortic Distensibility Measured by Automated Analysis of Magnetic Resonance Imaging Predicts Adverse Cardiovascular Events in UK Biobank.
in Journal of the American Heart Association
Topriceanu C
(2022)
APOE e 4 carriage associates with improved myocardial performance in older age
Kuo CL
(2020)
ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants.
in Aging
Banman A
(2023)
ApoE Modifier Alleles for Alzheimer's Disease Discovered by Information Theory Dependency Measures: MIST Software Package.
in Journal of computational biology : a journal of computational molecular cell biology
Li T
(2022)
APOE, TOMM40, and sex interactions on neural network connectivity.
in Neurobiology of aging
Zhu A
(2022)
APOE4 genotype associations with longitudinal change in hippocampal microstructure
in Alzheimer's & Dementia
Ibi D
(2022)
Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses.
in Journal of lipid research
Xu Y
(2022)
Apolipoprotein E moderates the association between Non- APOE Polygenic Risk Score for Alzheimer's Disease and Aging on Preclinical Cognitive Function
in Alzheimer's & Dementia
Haworth S
(2019)
Apparent latent structure within the UK Biobank sample has implications for epidemiological analysis.
in Nature communications
Jalali-Najafabadi F
(2021)
Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models.
in Scientific reports
Green HD
(2022)
Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank.
in British journal of cancer
Larsson SC
(2022)
Appraising the causal role of smoking in multiple diseases: A systematic review and meta-analysis of Mendelian randomization studies.
in EBioMedicine
Wang K
(2023)
Appraising the Effects of Metabolic Traits on the Risk of Glaucoma: A Mendelian Randomization Study.
in Metabolites
Batty GD
(2021)
Are a lack of social relationships and cigarette smoking really equally powerful predictors of mortality? Analyses of data from two cohort studies.
in Public health in practice (Oxford, England)
Nave G
(2019)
Are Bigger Brains Smarter? Evidence From a Large-Scale Preregistered Study.
in Psychological science
Sarkar C
(2018)
Are exposures to ready-to-eat food environments associated with type 2 diabetes? A cross-sectional study of 347 551 UK Biobank adult participants.
in The Lancet. Planetary health
Muzambi R
(2022)
Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records
in Translational Psychiatry
Tapela NM
(2022)
Are polygenic risk scores for systolic blood pressure and LDL-cholesterol associated with treatment effectiveness, and clinical outcomes among those on treatment?
in European journal of preventive cardiology
Sandoval-Plata G
(2022)
Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case-control study using data from the UK Biobank.
in Rheumatology international
Cohen JB
(2022)
Arterial Stiffness and Diabetes Risk in Framingham Heart Study and UK Biobank.
in Circulation research
Vallée A
(2022)
Arterial Stiffness Determinants for Primary Cardiovascular Prevention among Healthy Participants
in Journal of Clinical Medicine
Vallée A
(2022)
Arterial stiffness nomogram identification by cluster analysis: A new approach of vascular phenotype modeling.
in Journal of clinical hypertension (Greenwich, Conn.)
Wang M
(2022)
Arterial Stiffness, Genetic Risk, and Type 2 Diabetes: A Prospective Cohort Study.
in Diabetes care
Basty N
(2023)
Artifact-free fat-water separation in Dixon MRI using deep learning
in Journal of Big Data
Rudnicka AR
(2022)
Artificial intelligence-enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction and stroke.
in The British journal of ophthalmology
Trinder M
(2020)
Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia
in Journal of the American College of Cardiology
Ewbank F
(2023)
Aspirin and Subarachnoid Haemorrhage in the UK Biobank.
in Translational stroke research
Clifton L
(2022)
Assessing agreement between different polygenic risk scores in the UK Biobank.
in Scientific reports
Chen H
(2022)
Assessing Causal Associations of Atopic Dermatitis With Heart Failure and Other Cardiovascular Outcomes: A Mendelian Randomization Study.
in Frontiers in cardiovascular medicine
Yuan S
(2021)
Assessing causal associations of obesity and diabetes with kidney stones using Mendelian randomization analysis.
in Molecular genetics and metabolism
Ni JJ
(2021)
Assessing causal relationship from gut microbiota to heel bone mineral density.
in Bone
DeBoever C
(2020)
Assessing Digital Phenotyping to Enhance Genetic Studies of Human Diseases.
in American journal of human genetics
Hung RJ
(2021)
Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model.
in Cancer research
Pham D
(2022)
Assessing polygenic risk score models for applications in populations with under-represented genomics data: an example of Vietnam
in Briefings in Bioinformatics
Dudding T
(2018)
Assessing the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal cancer using Mendelian randomization.
in International journal of cancer
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |